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Abstract 
Dear Editor: Accumulated evidence suggests that serotonin 2A (5-HT2A) receptors are implicated in the 
pathology of schizophrenia. However the results remain inconclusive, particularly in the case of binding 
studies using postmortemtissue.We agreewith Dean's comment that our recent paper (Kang et al., 2009) 
reported a decrease in the density of [3H] ketanserin binding to the 5-HT2A receptors in the superior 
temporal gyrus (STG), which supported earlier findings in the planum temporal cortex (Pralong et al., 
2000), despite Burnet et al. reporting previously that there was no change in [3H] ketanserin binding in the 
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Dear Editor: 
Accumulated evidence suggests that serotonin 2A (5-HT2A) receptors are implicated in 
the pathology of schizophrenia. However the results remain inconclusive, particularly in 
the case of binding studies using postmortem tissue. We agree with Dean’s comment that 
our recent paper (Kang et al., 2009) reported a decrease in the density of [3H] ketanserin 
binding to the 5-HT2A receptors in the superior temporal gyrus (STG), which supported 
earlier findings in the planum temporal cortex (Pralong et al., 2000), despite Burnet et al. 
reported previously that there was no change in [3H] ketanserin binding in the STG in 
schizophrenia (Burnet et al., 1996). The controversy has also been the case in studies on 
[3H] ketanserin binding density in the dorsolateral prefrontal cortex and hippocampus in 
schizophrenia, even when reports have arisen from the same laboratory (Scarr et al., 
2004, Matsumoto et al., 2005) and using tissue from same cohort of subjects (Dean and 
Hayes, 1996, Dean et al., 1996). Recently, Dean and his colleagues have provided 
evidence to show that confounding [3H] ketanserin binding results in the dorsolateral 
prefrontal cortex of schizophrenia subjects were due to the employment of different 
methodologies, whereby a decrease in [3H] ketanserin binding in the dorsolateral 
prefrontal cortex in schizophrenia could only be detected by binding experiments on 
tissue sections and in crude homogenate, not on washed membranes (Dean et al., 2008). 
Dean and colleagues tried to extend this finding to the whole CNS (Dean et al., 2008), 
however this extension was not supported by their results in the STG and hippocampus 
(Pralong et al., 2000, Scarr et al., 2004, Matsumoto et al., 2005). Using tissue from the 
same cohort of subjects for studies in the dorsolateral prefrontal cortex, Dean and 
colleagues observed a decrease in the density of 5-HT2A receptors in the STG of 
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schizophrenia subjects using [3H] ketanserin binding techniques in both tissue sections 
and washed membranes (Pralong et al., 2000); findings that were opposite to those 
reported in the dorsolateral prefrontal cortex (Dean and Hayes, 1996, Dean et al., 1996). 
Even more interesting, the Bmax measured by both binding methods used in the STG were 
significantly correlated (r2 = 0.501, p=0.024) (Pralong et al., 2000). On the other hand, 
decreased [3H] ketanserin binding in the hippocampus was reported in one of their studies 
(Scarr et al., 2004) but not the other (Matsumoto et al., 2005), despite using the same 
binding method (ie: in tissue sections). Unfortunately, these opposing results appear to be 
omitted in Dean’s comments and earlier paper (Dean et al., 2008). Therefore, if these 
results are correct, caution should be given if extending the findings reported in the 
dorsolateral prefrontal cortex to other CNS regions.  
 
As various neurotransmitter receptor systems (eg. dopamine D2, GABAA, 5-HT2A etc. 
receptors) are involved in the pathology of schizophrenia (Wong and Van Tol, 2003), it is 
important to understand how these neurotransmitter systems interacted. We recognized 
that Dean has made a contribution in revealing the relationships among dopamine D2, 
GABAA, 5-HT2A, and muscarinic M1 receptor alterations in the dorsolateral prefrontal 
cortex in schizophrenia (Dean, 2001). Our recent studies of the pathological changes of 
GABAA, 5-HT2A, and muscarinic M1 receptors in the STG (Deng and Huang, 2005, 
Deng and Huang, 2006, Deng et al., 2007, Kang et al., 2009) provide an opportunity for 
us to explore the relationships among these receptors in the STG and their possible roles 
in the pathology of schizophrenia. Regarding the present study, we would like to clarify 
that, schizophrenia and control data were combined due to the relative low sample size (8 
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schizophrenia subjects and 8 controls), and Spearmans correlation test was employed to 
assess the relationships between the bindings of various receptors (Kang et al., 2009). We 
would also take this opportunity to correct a typographical error in the correlation 
between 5-HT2A and GABAA receptors (corrected to r=-0.47, p=0.066). These correlation 
data represent possible interactions between these receptors, and we agree with Dean’s 
comments that one should be cautious when interpreting these relationship results. 
Further studies to identify the mechanisms for the interactions between various 
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